Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Research context
Arecor Therapeutics PLC appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about AREC.LSE.